Sanofi disclosed its total number of issued shares and voting rights as of May 31, 2026. The company has issued 1,214,099,027 shares, with 1,333,575,416 real voting rights excluding treasury shares, and a theoretical total of 1,349,603,933 voting rights including treasury shares. This update is part of regulatory compliance under French commercial and stock market laws. Investors can access this information on Sanofi's official website for transparency and governance purposes.
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
